Tenofovir (TDF) has been demonstrated to have potency antiviral against the hepatitis B virus
(HBV) in various multiple-centre trials, with no cases of resistance encountered. However,
its efficacy and resistance profile in the Asian population, which constitute the majority of
chronic hepatitis B (CHB) patients, is unknown. Compared to other nucleoside analogues, TDF
has been associated with relatively high rates of hepatitis B surface antigen (HBsAg)
seroclearance. It would be interested to see if this could be reproduced. The investigators
plan to report the serologic and virologic results of our 140 nucleoside analogue-experienced
patients who were commenced on TDF.